rs80338714
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PVS1_ModeratePP5_Very_Strong
The NM_000047.3(ARSL):c.1743G>A(p.Trp581Ter) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000184 in 1,198,580 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 8 hemizygotes in GnomAD. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000047.3 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 10 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ARSL | NM_000047.3 | c.1743G>A | p.Trp581Ter | stop_gained | 11/11 | ENST00000381134.9 | NP_000038.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ARSL | ENST00000381134.9 | c.1743G>A | p.Trp581Ter | stop_gained | 11/11 | 1 | NM_000047.3 | ENSP00000370526 | P4 |
Frequencies
GnomAD3 genomes AF: 0.0000270 AC: 3AN: 111127Hom.: 0 Cov.: 22 AF XY: 0.0000600 AC XY: 2AN XY: 33335
GnomAD3 exomes AF: 0.00000568 AC: 1AN: 175970Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 61106
GnomAD4 exome AF: 0.0000175 AC: 19AN: 1087453Hom.: 0 Cov.: 29 AF XY: 0.0000169 AC XY: 6AN XY: 354405
GnomAD4 genome AF: 0.0000270 AC: 3AN: 111127Hom.: 0 Cov.: 22 AF XY: 0.0000600 AC XY: 2AN XY: 33335
ClinVar
Submissions by phenotype
X-linked chondrodysplasia punctata 1 Pathogenic:7Other:1
Pathogenic, criteria provided, single submitter | clinical testing | Centogene AG - the Rare Disease Company | - | - - |
not provided, no classification provided | literature only | GeneReviews | - | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Oct 07, 2022 | Criteria applied: PVS1_MOD, PS4, PM2_SUP - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Mar 01, 2003 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen | Nov 30, 2023 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Biochemical Molecular Genetic Laboratory, King Abdulaziz Medical City | Feb 05, 2020 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | May 30, 2023 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Laboratory of Medical Genetics, National & Kapodistrian University of Athens | May 23, 2024 | PVS1, PM2, PP5-The variant is expected to result in an absent or disrupted protein product. Low frequency in gnomAD population databases. It has been reported in ClinVar as Pathogenic by other laboratories (Variation ID: 11529). It has been previously reported as causative for chondrodysplasia punctata (PMID: 9863597, 12567415) - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 30, 2024 | The c.1743G>A (p.W581*) alteration, located in exon 11 (coding exon 10) of the ARSL gene, consists of a G to A substitution at nucleotide position 1743. This changes the amino acid from a tryptophan (W) to a stop codon at amino acid position 581. This alteration occurs at the 3' terminus of the ARSL gene, is not expected to trigger nonsense-mediated mRNA decay, and only impacts the last 1.5% of the protein. The exact functional effect of this alteration is unknown. Based on data from gnomAD, the c.1743G>A allele has an overall frequency of 0.001% (2/197636) total alleles studied, with 1 hemizygote observed. The highest observed frequency was 0.002% (2/89531) of European (non-Finnish) alleles. This variant was reported in multiple individuals with features consistent with ARSL-related chondrodysplasia punctata (Sheffield, 1998; Brunetti-Pierri, 2003; Mazzone, 2019; Bertoli-Avella, 2021). Based on the available evidence, this alteration is classified as pathogenic. - |
Chondrodysplasia punctata, brachytelephalangic, autosomal Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 03, 2024 | This sequence change creates a premature translational stop signal (p.Trp581*) in the ARSE gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 9 amino acid(s) of the ARSE protein. This variant is present in population databases (rs80338714, gnomAD 0.002%). This premature translational stop signal has been observed in individuals with chondrodysplasia punctata (PMID: 9863597, 12567415). ClinVar contains an entry for this variant (Variation ID: 11529). For these reasons, this variant has been classified as Pathogenic. - |
See cases Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Centre for Mendelian Genomics, University Medical Centre Ljubljana | Feb 18, 2020 | This variant was classified as: Likely pathogenic. The following ACMG criteria were applied in classifying this variant: PVS1,PM2. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Sep 04, 2024 | Nonsense variant predicted to result in protein truncation as the last 9 amino acids are lost, although loss-of-function variants have not been reported downstream of this position in the protein; This variant is associated with the following publications: (PMID: 9863597, 34529350, 32860008, 19839041, 30084160, 12567415, 26526591) - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at